AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 193 filers reported holding AUDENTES THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 5.36 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $1,405,000 | -50.5% | 50,000 | -33.3% | 0.09% | -47.2% |
| Q2 2019 | $2,840,000 | -27.2% | 75,000 | -25.0% | 0.16% | -38.3% |
| Q1 2019 | $3,902,000 | +50.3% | 100,000 | -17.9% | 0.26% | +25.1% |
| Q4 2018 | $2,597,000 | -47.5% | 121,797 | -2.6% | 0.21% | -34.5% |
| Q3 2018 | $4,949,000 | -59.9% | 125,000 | -61.3% | 0.32% | -64.7% |
| Q2 2018 | $12,340,000 | +27.2% | 322,945 | 0.0% | 0.91% | +26.3% |
| Q1 2018 | $9,704,000 | -8.1% | 322,945 | -4.4% | 0.72% | -34.6% |
| Q4 2017 | $10,559,000 | +16.5% | 337,876 | +4.4% | 1.10% | -30.9% |
| Q3 2017 | $9,062,000 | +46.4% | 323,545 | 0.0% | 1.60% | +55.9% |
| Q2 2017 | $6,189,000 | -14.5% | 323,545 | -23.8% | 1.03% | -2.4% |
| Q1 2017 | $7,236,000 | -11.9% | 424,660 | -5.6% | 1.05% | -5.1% |
| Q4 2016 | $8,215,000 | +2.6% | 449,660 | 0.0% | 1.11% | +25.4% |
| Q3 2016 | $8,008,000 | – | 449,660 | – | 0.88% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,204,615 | $37,644,219,000 | 39.61% |
| Casdin Capital, LLC | 400,000 | $12,500,000 | 3.04% |
| Opaleye Management Inc. | 210,000 | $6,652,000 | 2.13% |
| Orbimed Advisors | 4,129,638 | $129,051,000 | 1.63% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,190,516 | $37,204,000 | 1.46% |
| Redmile Group, LLC | 929,326 | $29,041,000 | 1.26% |
| Cormorant Asset Management, LP | 337,876 | $10,559,000 | 1.10% |
| Perceptive Advisors | 781,309 | $24,416,000 | 0.81% |
| Rock Springs Capital Management LP | 525,000 | $16,406,000 | 0.74% |
| Virtus ETF Advisers LLC | 11,898 | $372,000 | 0.47% |